KCNG3 and cancer: This effect has been corroborated by in-vitro and in-vivo pharmacological studies using non-selective Kv10.1-blockers or siRNA, both showing positive results (Table 2), i.e., reducing proliferation rate in cancer cell lines or xenograft tumor size in immunodeficient mice [24,31,32,49,50,51,52].